For people with Graves' disease who relapse, whether they choose long-term methimazole, radioactive iodine, or a second round of methimazole, their risk of worsening eye problems and their overall quality of life remain similar over many years.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether treatment modality for relapsed Graves' disease consistently influences TED progression or quality of life across diverse populations and follow-up durations.
A systematic review and meta-analysis of all prospective studies comparing TED progression (CAS score change) and quality of life (ThyPRO-39 or similar) in patients with relapsed Graves' disease treated with continuous MMI, RAI, or second-course MMI, with minimum 3-year follow-up.
An RCT would determine whether assigning patients to different treatments causally affects TED progression or quality of life, independent of baseline severity.
A multicenter RCT of 200 adults with relapsed Graves' disease and mild TED (CAS ≤3), randomized to continuous MMI, RAI, or second-course MMI. Primary outcomes: change in CAS score and ThyPRO-39 score at 2 and 5 years. Secondary: incidence of TED worsening requiring steroids. All patients receive TED monitoring and prophylaxis per guidelines.
A prospective cohort with standardized TED and QoL assessments could confirm whether treatment choice influences these outcomes after adjusting for baseline severity.
A prospective cohort of 300 adults with relapsed Graves' disease, stratified by baseline TED severity (CAS 0–3 vs. 4–7), followed for 5 years with quarterly CAS and annual ThyPRO-39 assessments. Treatment group assigned prospectively. Multivariate analysis adjusts for smoking, TRAb, and baseline TED.
A case-control study could identify whether patients with TED progression after treatment differ in treatment type, smoking, or TRAb levels from those without progression.
A case-control study comparing 60 patients with TED progression (CAS increase ≥2) to 60 without progression, matched for age, sex, and baseline CAS. Exposure variables: treatment type, smoking status, TRAb levels, and steroid use.
A cross-sectional survey could estimate current TED status and QoL in patients with relapsed Graves' disease by treatment type, but cannot assess change over time.
A cross-sectional survey of 500 adults with relapsed Graves' disease, measuring current CAS score and ThyPRO-39 score by treatment group (continuous MMI, RAI, second-course MMI).